(Sharecast News) - CelLBxHealth said in an update on Friday that it expected to report lower-than-anticipated revenues for 2025 after the deferral of several sales contracts, while highlighting a strong cash position and significant cost reductions as it positions the business for commercial progress in 2026.
The AIM-traded circulating tumour cell...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE